Tag

durvalumab

CT scans of the chest and abdomen of a patient with metastatic small cell lung cancer

Tarlatamab extends small cell lung cancer survival by 8 months

Adding tarlatamab to durvalumab maintenance raised median survival from 12.7 to 21.1 months in extensive-stage small cell lung cancer, with mostly mild immune reactions.

24 October 2026

Medical illustration showing the location of the bladder and a tumour growing in the bladder wall

Oncology

Drugs around bladder surgery help people who can't have cisplatin

In the VOLGA trial, durvalumab plus enfortumab vedotin around bladder removal lifted two-year survival from 69% to 78% for people who couldn't or wouldn't have cisplatin.

24 October 2026